Vaccines
AssigneeSmithKline Beecham Biologicals s.a.
InventorsPatricia Marie Momin, Nathalie Marie-Josephe Garcon
Life of this patent
Estimating the term…
Abstract
The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.
Claims15
A vaccine composition comprising an antigen and/or antigenic composition, QS21, 3-De-O-acylated monophosphoryl lipid A (3D-MPL) and an oil in water emulsion wherein the oil in water emulsion comprises a metabolizable oil, alpha tocopherol and TWEEN 80 (polyoxyethelene sorbitan monooleate).
An immunogenic composition comprising an antigen and/or antigenic composition, QS21, 3-De-O-acylated monophosphoryl lipid A (3D-MPL) and an oil in water emulsion wherein the oil in water emulsion comprises a metabolizable oil, alpha tocopherol and TWEEN 80 (polyoxyethelene sorbitan monooleate) wherein said antigen and/or antigenic composition is selected from the group consisting of Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E, Respiratory Syncytial Virus, Human papilloma Virus, Influenza Virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium and Toxoplasma.
An immunogenic composition comprising an antigen and/or antigenic composition, QS21, 3-De-O-acylated monophosphoryl lipid A (3D-MPL) and an oil in water emulsion wherein the oil in water emulsion comprises a metabolizable oil, alpha tocopherol and TWEEN 80 (polyoxyethelene sorbitan monooleate) wherein the antigen and/or antigenic composition is a tumor antigen.
An immunogenic composition comprising an antigen and/or antigenic composition, QS21, 3-De-O-acylated monophosphoryl lipid A (3D-MPL) and an oil in water emulsion wherein the oil in water emulsion comprises a metabolizable oil, alpha tocopherol and TWEEN 80 (polyoxyethelene sorbitan monooleate) wherein said antigen and/or antigenic composition is selected from the group consisting of Human Immunodeficiency Virus and Feline Immunodeficiency Virus.
Dependencies are inferred from the claim text.